José Baselga
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
Papers in
- Oncology 221
- HER2/EGFR in Cancer Research 141
- Cancer Treatment and Pharmacology 77
- Colorectal Cancer Treatments and Studies 34
- Peptidase Inhibition and Analysis 26
-
- PI3K/AKT/mTOR signaling in cancer 31
- Co-authors
- John Mendelsohn (7 shared papers)Larry Norton (13 shared papers)Mark D. Pegram (2 shared papers)W. Eiermann (9 shared papers)Brian Leyland‐Jones (6 shared papers)Thomas Fleming (1 shared paper)Janet Wolter (1 shared paper)Dennis J. Slamon (1 shared paper)
- Journals
- Journal of Clinical Oncology (78 papers)Cancer Research (28 papers)Clinical Cancer Research (23 papers)Annals of Oncology (23 papers)European Journal of Cancer (7 papers)
- Partner nations
- SpainUnited StatesSwitzerland
In The Last Decade
José Baselga
270 papers receiving 48.1k citations
José Baselga's Hit Papers
Peers
Comparison fields: 5 of 168
- Oncology 34.9k
- Cancer Research 9.4k
- Radiology, Nuclear Medicine and Imaging 12.4k
- Pulmonary and Respiratory Medicine 13.6k
- Genetics 2.8k
Countries citing papers authored by José Baselga
This map shows the geographic impact of José Baselga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Baselga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Baselga more than expected).
Fields of papers citing papers by José Baselga
This network shows the impact of papers produced by José Baselga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Baselga. The network helps show where José Baselga may publish in the future.
Co-authors
The 25 scholars most cited alongside José Baselga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 273 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 8436 |
| 2 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 2665 |
| 3 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2003 | 2392 |
| 4 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Hit paper breakdown → | 2011 | 1773 |
| 5 | Genomic analysis identifies association of Fusobacterium with colorectal carcinoma Hit paper breakdown → | 2011 | 1444 |
| 6 | The EGF receptor family as targets for cancer therapy Hit paper breakdown → | 2000 | 1099 |
| 7 | Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer Hit paper breakdown → | 2003 | 1022 |
| 8 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Hit paper breakdown → | 2017 | 918 |
| 9 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Hit paper breakdown → | 2009 | 912 |
| 10 | Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Hit paper breakdown → | 2007 | 898 |
| 11 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2010 | 891 |
| 12 | Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Hit paper breakdown → | 1998 | 811 |
| 13 | AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity Hit paper breakdown → | 2011 | 746 |
| 14 | Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer Hit paper breakdown → | 2010 | 701 |
| 15 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 683 |
| 16 | Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer Hit paper breakdown → | 2007 | 659 |
| 17 | PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization Hit paper breakdown → | 2002 | 642 |
| 18 | Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Hit paper breakdown → | 2001 | 614 |
| 19 | Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin Hit paper breakdown → | 2000 | 596 |
| 20 | Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer Hit paper breakdown → | 2005 | 596 |
About José Baselga
José Baselga is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 273 papers that have together received 49.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (141 papers), Cancer Treatment and Pharmacology (77 papers), Monoclonal and Polyclonal Antibodies Research (59 papers), Lung Cancer Treatments and Mutations (45 papers), Colorectal Cancer Treatments and Studies (34 papers), Advanced Breast Cancer Therapies (34 papers), PI3K/AKT/mTOR signaling in cancer (31 papers) and Peptidase Inhibition and Analysis (26 papers). The work is most often cited by research in Oncology (34.9k citations), Cancer Research (9.4k citations), Radiology, Nuclear Medicine and Imaging (12.4k citations), Pulmonary and Respiratory Medicine (13.6k citations) and Genetics (2.8k citations). José Baselga has collaborated with scholars based in Spain, United States and Switzerland. Frequent co-authors include John Mendelsohn, Larry Norton, Mark D. Pegram, W. Eiermann, Brian Leyland‐Jones, Thomas Fleming, Janet Wolter, Dennis J. Slamon, Alex Bajamonde and Virginia Paton. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.